Across TCGA pan-cancer cohorts, CLDN4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLDN4 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLDN4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN4 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

HNSC, SARC, and SKCM are the cancer types where CLDN4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.191	0.751	.003	12	view →
SARC	DFS	Median	All	0.115	0.613	.002	9	view →
SKCM	DFS	Median	II,III,IV	0.935	0.665	.039	3	view →
UCEC	DFS	Median	All	1.000	0.636	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CLDN4 tumor-vs-normal RNA expression · all CLDN4 data types